Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Trial Profile

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Portal hypertension; Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms ANGEL; Portopulm
  • Most Recent Events

    • 23 Apr 2018 Planned End Date changed from 1 Sep 2017 to 1 Oct 2018.
    • 24 May 2017 Primary endpoint (6 minute walk distance (6MWD)) has not been met as per the results presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Primary endpoint (Pulmonary vascular resistance (PVR)) has been met as per the results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top